The Trump administration recently cancelled billions of dollars in funding to the NIH. Healthcare experts say the funding cuts will delay the pace of medical research in the U.S. — which will not only hamper the commercialization of life-saving treatments, but could also hurt the country’s position as a global leader in healthcare and technology.
President Donald Trump selected Susan Monarez — the current acting director of the Centers for Disease Control and Prevention — to lead the agency going forward. This nomination replaces one that the White House withdrew on March 13, after it became clear that physician and former Republican congressman Dave Weldon would not receive enough Senate votes to be confirmed.
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
President Donald Trump’s latest executive order aims to strengthen enforcement for CMS’ price transparency requirements. Some experts think greater price transparency could reduce healthcare costs by fostering more competition, while others are concerned about the potential effects on hospital-payer negotiations, as well as the practicality of enforcing these requirements.
President-Elect Donald Trump nominated celebrity physician Dr. Mehmet Oz to lead CMS. Healthcare leaders have mixed feelings on the news — for instance, one CEO pointed out that Dr. Oz could advance the food-as-medicine movement, and others noted that his appointment may decrease pharmaceutical innovation and access to certain medications.
Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.
When it comes to the effects that the upcoming Trump presidency will have on healthcare, attendees' attitudes ranged from cautiously optimistic to fairly anxious. Some of the issues they highlighted included mental health parity, telehealth prescribing flexibilities, and the role of Robert F. Kennedy Jr.
Help shape the future of healthcare benefits by sharing your insights.
Experts from BRG recently discussed the two presidential candidates' stances on key healthcare issues, including drug pricing, Medicaid and AI.
A new CMS proposed rule aims to make significant changes to Affordable Care Act marketplaces, including increasing the annual open enrollment period by a month and restoring the duties of navigators who help consumers from underserved populations enroll in plans on the federally facilitated exchange.
After scrapping work requirements for Medicaid eligibility in four states, CMS has added Arizona and Indiana to the list. These requirements have long been controversial, facing litigation and strong opposition, but proponents say they incentivize people to find jobs.
In a move that ACOs found "disappointing," CMS has declined to extend the Next Generation ACO Model beyond 2021. Though evaluations have found that the model did not generate net savings for Medicare, proponents argue that the program was successful.
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
In a wide-ranging interview, the National Coordinator for Health IT Dr. Micky Tripathi discussed his career and how his varied experiences have expanded his perspective. He also spoke about ONC's plans for the future, which include "evangelizing" about the opportunities the federal interoperability rules will create for the industry.
Aetna will now cover breast augmentation for trans women, signaling hope for increased access to healthcare for the transgender community. The coverage expansion comes after transgender individuals and groups advocated for the change.
After declaring a state of emergency on Friday, Trump announced that Google would be building a website that could route users to drive-thru testing sites for COVID-19. Alphabet’s subsidiary, Verily, said the tool was in the early stages of development, and that it planned to roll out testing in the Bay Area.
While AWS, Intel, Cisco, and others pull out of a large health IT conference in Orlando due to Covid-19 fears, President Donald Trump will be traveling there to address the issue of interoperability in healthcare.
Equity research analysts wrote in a note Thursday that the move could have a beneficial read-across to another drug that has the same target as Repatha.